BI: Extended-release Viramune XR works as well as predecessor

VIENNA A once-daily formulation of an HIV drug made by Boehringer Ingelheim works as well as the twice-daily version, according to results of a study presented Thursday at the 18th annual International AIDS Conference in Vienna.

BI presented results of the VERxVE study, showing that extended-release Viramune XR (nevirapine) worked as well as immediate-release Viramune IR through the 48 weeks of the study.

The drug was effective across patient profiles and did not produce any identifiable new side effects.